LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
HHKEX:229113.99
HKD
-0.03
(-0.21%)
ISIN
CNE1000057M5
Return %
Stock
S&P 500
1Y
-27.81
14.20
3Y
-51.68
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Juan Chen
- Full Time Employees
- 370
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Building 41 Shanghai SH China 201612
- IPO Date
- Nov 8, 2022
- Website
- scientechmed.com
- Similar Companies
- Business
- LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK) engages in the research, development, manufacture and commercialization of interventional medical devices targeting structural heart diseases, including congenital heart disease occluders, heart valves and procedural accessories. Founded in 1994 and headquartered in Shanghai, China, the company operates primarily in China with products marketed in over 60 countries and regions. Its core products encompass 29 marketed items across occluder business and heart valve business segments; occluder products include MemoPart ASD, VSD and PDA occluders (double-rivet and single-rivet variants), MemoCarna oxide coating occluders, MemoSorb and NeoSorb fully-degradable and biodegradable occluders for ASD, VSD, PDA and PFO, MemoLefort and Bio-Lefort LAA occluders, MemoPart and MemoSorb PFO occluders, as well as aortic, peripheral and embolization occluders; heart valve products feature ScienCrown transcatheter aortic valve replacement (TAVR) system, ScienChute transcatheter aortic valve stenosis therapy system, transcatheter aortic valve system for regurgitation, ScienMelon artificial heart valve, MemoChord transapical mitral valve repair system, MemoClip-A and MemoClip-F transapical and transfemoral mitral valve clip repair systems, and transcatheter mitral valve replacement system; pathway and procedural accessories comprise RF-Lance radiofrequency atrial septal puncture needles and devices, interventional delivery systems (MemoPart, Gruiser, G-Cruiser, GuiFinder, GuiFlex, GuiBend), snares, balloon dilatation catheters for aortic valve, disposable introducing sheaths, guide wires, vascular closure devices, thrombus protection devices and multiple-loop snares; mechanical circulatory support products in development include interatrial shunt devices, transcatheter left ventricular support systems and coronary protection systems. In 2024, the company achieved revenue of RMB471.6 million, up 44.4% from RMB326.6 million in 2023, driven by 396.6% growth in PFO and LAA occluder sales to RMB143.9 million from successful commercialization of biodegradable PFO occluders and steady CHD occluder revenue of RMB245.9 million; key approvals included NMPA registration for MemoSorb IV biodegradable ASD occluder in August 2024, RF-Lance products in April and July 2024, ScienCrown TAVR in December 2024 and balloon dilatation catheter for aortic valve at year-end, with net profit rising 62.2% to RMB245.6 million; it renewed the Entrusted Products Related Framework Agreement with controlling shareholder Lepu Medical in October 2024 for three years from January 2025, enabling purchase of TAVR systems manufactured by Lepu Medical upon commercialization for exclusive sales and distribution, with proposed annual caps of RMB40 million in 2025, RMB60 million in 2026 and RMB80 million in 2027 based on estimated sales volumes and manufacturing costs plus 10% profit markup.